WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

OpenEvidence is free for now. Its CEO has a plan for who will pay.

OpenEvidence chief Daniel Nadler says he envisions changing the company’s ad-supported model, which has kept it free for medical professionals and driven its widespread adoption.

Raccontata danbcnews.comgizmodo.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
nbcnews.comStai leggendo1 mesi fa

OpenEvidence is free for now. Its CEO has a plan for who will pay.

OpenEvidence chief Daniel Nadler says he envisions changing the company’s ad-supported model, which has kept it free for medical professionals and driven its widespread adoption.

originale
gizmodo.com1 mesi fa

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says

65% of U.S. doctors reportedly use OpenEvidence, which is supported in part by pharmaceutical ads.

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 13 maggio 2026·nbcnews.com

    OpenEvidence is free for now. Its CEO has a plan for who will pay.

    OpenEvidence chief Daniel Nadler says he envisions changing the company’s ad-supported model, which has kept it free for medical professionals and driven its widespread adoption.

  2. giovedì 14 maggio 2026·gizmodo.com

    Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says

    65% of U.S. doctors reportedly use OpenEvidence, which is supported in part by pharmaceutical ads.